Corbion: Sales and Margins Decline in Q1, but Company Bets on Rebound from Q2
Corbion recorded a contraction in its sales and earnings in the first quarter of 2026, impacted by unfavorable comparisons with the previous year and a planned shift in its nutrition business. Despite this, the sustainable ingredients giant maintains its annual guidance, expecting a return to growth starting in the second quarter and the implementation of a cost reduction program to preserve its margins.
Q1 2026 Financial Results
Corbion has released its results for the first quarter of 2026. The group experienced negative growth in sales and profits compared to the first quarter of 2025. This decline reflects two specific factors: on one hand, a particularly high level of comparison recorded a year earlier in the Functional Ingredients & Solutions activity, and on the other hand, a temporary shift in the Nutrition activity, planned in the company's annual schedule. Adjusted EBITDA margins contracted by 360 basis points, mainly due to product mix effects and low operational efficiency linked to the temporary sales slump in the Health & Nutrition activity.
Anticipated Turnaround from Q2
The group expects a reversal of trend starting from the second quarter. According to Olivier Rigaud, CEO of Corbion, sales in the Health & Nutrition sector are expected to accelerate from Q2 onwards and more than compensate for the decline recorded in the first quarter. The company anticipates a return to positive growth in volume and mix for the remaining quarters of the year. To support its annual guidance for adjusted EBITDA margin, Corbion has already launched an operational cost reduction program, with savings starting to manifest from Q2.
Reaffirmation of Full-Year 2026 Guidance
Corbion reaffirms its entire guidance for the fiscal year 2026, in terms of sales growth, adjusted EBITDA margin, and free cash flow. However, management cites macroeconomic and geopolitical challenges, including the conflict in the Middle East, as factors generating pressures on prices and supply chains. The company asserts that it is implementing appropriate measures to address these issues. This confirmation of guidance, despite a disappointing opening quarter, is based on the anticipation of a seasonal normalization of the Nutrition activity and the increasing impact of the cost control program throughout the year.
